Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489318 · ClinicalTrials.gov registry record · Phase 3
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
A Phase 3 study of Prostate Cancer, sponsored by Aragon Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,052
- Enrollment target
- 20
- Study locations
NCT02489318 is a Phase 3 study of Prostate Cancer that is active but no longer recruiting, run by Aragon Pharmaceuticals. The registered enrollment target is 1,052 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT02489318, a Phase 3 study of Prostate Cancer, is active but no longer recruiting, sponsored by Aragon Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,052 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apalutamide
- DRUG Androgen Deprivation Therapy (ADT)
Study Locations (20)
New York
- - Brooklyn
- - Poughkeepsie
- - Syracuse
California
- - San Bernardino
- - San Diego
Indiana
- - Fort Wayne
- - Jeffersonville
Maryland
- - Baltimore
- - Rockville
Michigan
- - Lansing
- - Troy
Alabama
- - Homewood
Arizona
- - Tucson
Colorado
- - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,052 participants |
| Start Date | 2015-11-27 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02489318
The ClinicalTrials.gov registry entry for NCT02489318 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,052 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (73% higher). The listed sponsor is Aragon Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02489318 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT02489318 about?
NCT02489318 is a clinical study titled "A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC". The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
What is the current status of trial NCT02489318?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,052 participants. The study started on 2015-11-27. Estimated completion is 2027-12-31.
What conditions does trial NCT02489318 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02489318?
The interventions under investigation include: Placebo (DRUG), Apalutamide (DRUG), Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT02489318?
This trial is sponsored by Aragon Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02489318 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.